- Home
- THRY vs DNTH Comparison
THRY vs DNTH Comparison
Compare THRY & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THRY
- DNTH
- Stock Information
- Founded
- THRY 2003
- DNTH 2015
- Country
- THRY United States
- DNTH United States
- Employees
- THRY N/A
- DNTH N/A
- Industry
- THRY Industrial Machinery/Components
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- THRY Industrials
- DNTH Health Care
- Exchange
- THRY Nasdaq
- DNTH Nasdaq
- Market Cap
- THRY 703.2M
- DNTH 711.2M
- IPO Year
- THRY 2020
- DNTH N/A
- Fundamental
- Price
- THRY $15.39
- DNTH $23.62
- Analyst Decision
- THRY Strong Buy
- DNTH Strong Buy
- Analyst Count
- THRY 3
- DNTH 8
- Target Price
- THRY $24.33
- DNTH $46.43
- AVG Volume (30 Days)
- THRY 349.3K
- DNTH 192.9K
- Earning Date
- THRY 11-07-2024
- DNTH 11-07-2024
- Dividend Yield
- THRY N/A
- DNTH N/A
- EPS Growth
- THRY N/A
- DNTH N/A
- EPS
- THRY N/A
- DNTH N/A
- Revenue
- THRY $873,723,000.00
- DNTH $5,366,000.00
- Revenue This Year
- THRY N/A
- DNTH $98.73
- Revenue Next Year
- THRY N/A
- DNTH N/A
- P/E Ratio
- THRY N/A
- DNTH N/A
- Revenue Growth
- THRY N/A
- DNTH 51.41
- 52 Week Low
- THRY $13.06
- DNTH $6.58
- 52 Week High
- THRY $26.42
- DNTH $33.77
- Technical
- Relative Strength Index (RSI)
- THRY 43.67
- DNTH 47.82
- Support Level
- THRY $15.00
- DNTH $23.55
- Resistance Level
- THRY $16.66
- DNTH $24.65
- Average True Range (ATR)
- THRY 0.62
- DNTH 1.45
- MACD
- THRY -0.06
- DNTH 0.14
- Stochastic Oscillator
- THRY 4.35
- DNTH 38.79
About THRY Thryv Holdings Inc.
Thryv Holdings Inc provides software as service (SaaS) management tools and digital and print marketing tools to small and mid-sized businesses. The company operates in four reportable segments namely Thryv U.S. Marketing Services, Thryv U.S. SaaS, Thryv International Marketing Services, and Thryv International SaaS. It generates maximum revenue from the Thryv U.S. Marketing Services segment.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.